A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

When should pregnant women get the RSV vaccine? Research suggests that 32 weeks into pregnancy ensures the best antibody ...

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

The second is a new immunization available for pregnant patients, called Abrysvo, which leads to a 57% decrease in the chance of infant hospitalization due to RSV. Availability of nirsevimab is ...